The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice

Current Clinical Pharmacology

Volumn 8, Issue 2, 2013, Pages 135-155

  Maximov, Philipp Y ^a   Lee, Theresa M ^b   Craig Jordan, V ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Arzoxifene; Bazedoxifene; Lasofoxifene; Ospemifene; Raloxifene; Selective estrogen receptor modulator; Tamoxifen

Indexed keywords

AFIMOXIFENE; ARZOXIFENE; BAZEDOXIFENE; CYTOCHROME P450 2D6; DROLOXIFENE; ESTRADIOL; ICI 46464; LASOFOXIFENE; NORTAMOXIFEN; OSPEMIFENE; PROLACTIN; RALOXIFENE; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TAMOXIFEN CITRATE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BREAST CANCER; BREAST CARCINOGENESIS; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; CHOLECYSTITIS; CLINICAL PRACTICE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ESTROGEN ACTIVITY; GOLD STANDARD; HEART DISEASE; HOT FLUSH; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; LUNG COMPLICATION; MUSCLE CRAMP; NONHUMAN; OUTCOME ASSESSMENT; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPINE FRACTURE; THROMBOEMBOLISM; UTERUS CANCER; VAGINA ATROPHY; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM; VULVOVAGINITIS;

ANIMALS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG DISCOVERY; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84876883246     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574884711308020006     Document Type: Article

References (220)

1. Lacassagne A. Hormonal pathogenesis of adenocarcinoma of thebreast. Am J Cancer 1936; 27: 217-25.
2. Lerner LJ, Jordan VC. Development of antiestrogens and their usein breast cancer: eighth Cain memorial award lecture. Cancer Res1990; 50: 4177-89.
3. Lerner LJ, Holthaus FJ Jr., Thompson CR. A non-steroidalestrogen antiagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl ethanol. Endocrinology 1958; 63: 295-318.
4. Greenblatt RB, Barfield WE, Jungck EC, Ray AW. Induction ofovulation with MRL/41. Preliminary report. JAMA 1961; 178:101-4.
5. Greenblatt RB, Roy S, Mahesh VB. Induction of ovulation. Am JObstet Gynecol 1962; 84: 900-12.
6. Clark JH, Markaverich BM. The agonistic-antagonistic propertiesof clomiphene: a review. Pharmacol Ther 1981; 15: 467-519.
7. Harper MJ, Walpole AL. A new derivative of triphenylethylene:effect on implantation and mode of action in rats. J Reprod Fertil1967; 13: 101-19.
8. Harper MJ, Walpole AL. Mode of action of I.C.I. 46,474 inpreventing implantation in rats. J Endocrinol 1967; 37: 83-92.
9. Klopper A, Hall M. New synthetic agent for the induction ofovulation: preliminary trials in women. Br Med J 1971; 1: 152-4.
10. Williamson JG, Ellis JD. The induction of ovulation by tamoxifen. J Obstet Gynaecol Br Commonw1973; 80: 844-7.
11. Cole MP, Jones CT, Todd ID. A new anti-oestrogenic agent in latebreast cancer. An early clinical appraisal of ICI46474. Br J Cancer1971; 25: 270-5.
12. Ward HW. Anti-oestrogen therapy for breast cancer: a trial oftamoxifen at two dose levels. Br Med J 1973; 1: 13-4.
13. Jordan VC. Tamoxifen (ICI46,474) as a targeted therapy to treatand prevent breast cancer. Br J Pharmacol 2006; 147(Suppl 1):S269-76.
14. Jordan VC. Tamoxifen: a most unlikely pioneering medicine. NatRev Drug Discov 2003; 2: 205-13.
15. Jordan VC. Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer 2008; 44: 30-8.
16. Jordan VC. Biochemical pharmacology of antiestrogen action. Pharmacol Rev 1984; 36: 245-76.
17. Powles TJ, Hardy JR, Ashley SE, et al. A pilot trial to evaluate theacute toxicity and feasibility of tamoxifen for prevention of breastcancer. Bri J cancer 1989; 60: 126-31.
18. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC. Contrasting actions of tamoxifen on endometrial and breast tumorgrowth in the athymic mouse. Cancer Res 1988; 48: 812-5.
19. Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifenin early breast cancer: occurrence of new primary cancers. Lancet1989; 1: 117-20.
20. Gottardis MM, Jordan VC. Antitumor actions of keoxifene andtamoxifen in the N-nitrosomethylurea-induced rat mammarycarcinoma model. Cancer Res 1987; 47: 4020-4.
21. Jordan VC, Phelps E, Lindgren JU. Effects of anti-estrogens onbone in castrated and intact female rats. Breast Cancer Res Treat1987; 10: 31-5.
22. Jordan VC, Robinson SP. Species-specific pharmacology ofantiestrogens: role of metabolism. Fed Proc 1987; 46: 1870-4.
23. Jordan VC. Chemosuppression of breast cancer with tamoxifen:laboratory evidence and future clinical investigations. CancerInvest 1988; 6: 589-95.
24. Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen oncardiovascular risk factors in postmenopausal women. Ann InternMed 1991; 115: 860-4.
25. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen onbone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852-6.
26. Love RR, Newcomb PA, Wiebe DA, et al. Effects of tamoxifentherapy on lipid and lipoprotein levels in postmenopausal patientswith node-negative breast cancer. J Natl Cancer Inst 1990; 82:1327-32.
27. Jordan VC, Koch R, Mittal S, Schneider MR. Oestrogenic andantioestrogenic actions in a series of triphenylbut-1-enes:modulation of prolactin synthesis in vitro. Br J Pharmacol 1986;87: 217-23.
28. Lieberman ME, Gorski J, Jordan VC. An estrogen receptor modelto describe the regulation of prolactin synthesis by antiestrogens invitro. J Biol Chem 1983; 258: 4741-5.
29. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebralfracture risk in postmenopausal women with osteoporosis treatedwith raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE)Investigators. JAMA 1999; 282: 637-45.
30. Cummings SR, Eckert S, Krueger KA, et al. The effect ofraloxifene on risk of breast cancer in postmenopausal women:results from the MORE randomized trial. Multiple Outcomes ofRaloxifene Evaluation. JAMA 1999; 281: 2189-97.
31. Vogel VG, Costantino JP, Wickerham DL, et al. Effects oftamoxifen vs raloxifene on the risk of developing invasive breastcancer and other disease outcomes: the NSABP Study ofTamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295:2727-41.
32. Vogel VG, Costantino JP, Wickerham DL, et al. Update of theNational Surgical Adjuvant Breast and Bowel Project Study ofTamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breastcancer. Cancer Prev Res (Phila Pa) 2010; 3: 696-706.
33. Kenakin T. Inverse, protean, and ligand-selective agonism: mattersof receptor conformation. FASEB J 2001; 15: 598-611.
34. Miller CP. SERMs: evolutionary chemistry, revolutionary biology. Curr Pharm Des 2002; 8: 2089-111.
35. Jordan VC, Collins MM, Rowsby L, Prestwich G. Amonohydroxylated metabolite of tamoxifen with potentantioestrogenic activity. J Endocrinol 1977; 75: 305-16.
36. Allen KE, Clark ER, Jordan VC. Evidence for the metabolicactivation of non-steroidal antioestrogens: a study of structureactivityrelationships. Br J Pharmacol 1980; 71: 83-91.
37. Jordan VC, Allen KE. Evaluation of the antitumour activity of thenon-steroidal antioestrogen monohydroxytamoxifen in the DMBAinducedrat mammary carcinoma model. Eur J Cancer 1980; 16:239-51.
38. Jordan VC, Bain RR, Brown RR, Brown RR, Gosden B, SantosMA. Determination and pharmacology of a new hydroxylatedmetabolite of tamoxifen observed in patient during therapy foradvanced breast cancer. Cancer Res 1983; 43: 1446-50.
39. Johnson MD, Zuo H, Lee KH, et al. Pharmacologicalcharacterization of 4-hydroxy-N-desmethyl tamoxifen, a novelactive metabolite of tamoxifen. Breast Cancer Res Treat 2004; 85:151-9.
40. Lim YC, Desta Z, Flockhart DA, Skaar TC. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancercells with potency similar to 4-hydroxy-tamoxifen. CancerChemother Pharmacol 2005; 55: 471-8.
41. Lim YC, Li L, Desta Z, et al. Endoxifen, a secondary metabolite oftamoxifen, and 4-OH-tamoxifen induce similar changes in globalgene expression patterns in MCF-7 breast cancer cells. J PharmacolExp Ther 2006; 318: 503-12.
42. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifenmetabolite plasma concentrations after coadministration oftamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003; 95: 1758-64.
43. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressantuse, and tamoxifen metabolism during adjuvant breast cancertreatment. J Natl Cancer Inst 2005; 97: 30-9.
44. Borges S, Desta Z, Li L, et al. Quantitative effect of CYP2D6genotype and inhibitors on tamoxifen metabolism: implication foroptimization of breast cancer treatment. Clin Pharmacol Ther 2006;80: 61-74.
45. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics oftamoxifen biotransformation is associated with clinical outcomes ofefficacy and hot flashes. J Clin Oncol 2005; 23: 9312-8.
46. Gottardis MM, Jordan VC. Antitumor actions of keoxifene andtamoxifen in the N-nitrosomethylurea-induced rat mammarycarcinoma model. Cancer Res 1987; 47: 4020-4.
47. Jordan VC, Gosden B. Inhibition of the uterotropic activity ofestrogens and antiestrogens by the short acting antiestrogenLY117018. Endocrinology 1983; 113: 463-8.
48. Snyder KR, Sparano N, Malinowski JM. Raloxifene hydrochloride. Am J Health Syst Pharm 2000; 57: 1669-75; quiz 76-78.
49. Kemp DC, Fan PW, Stevens JC. Characterization of raloxifeneglucuronidation in vitro: contribution of intestinal metabolism topresystemic clearance. Drug Metab Dispos 2002; 30: 694-700.
50. Jeong EJ, Lin H, Hu M. Disposition mechanisms of raloxifene inthe human intestinal Caco-2 model. J Pharmacol Exp Ther 2004;310: 376-85.
51. Falany JL, Pilloff DE, Leyh TS, Falany CN. Sulfation of raloxifeneand 4-hydroxytamoxifen by human cytosolic sulfotransferases. Drug Metab Dispos 2006; 34: 361-8.
52. Jordan VC. Chemoprevention of breast cancer with selectiveoestrogen-receptor modulators. Nat Rev Cancer 2007; 7: 46-53.
53. Prakash C, Johnson KA, Schroeder CM, Potchoiba MJ. Metabolism, distribution, and excretion of a next generationselective estrogen receptor modulator, lasofoxifene, in rats andmonkeys. Drug Metab Dispos 2008; 36: 1753-69.
54. Rosati RL, Da Silva Jardine P, et al. Discovery and preclinicalpharmacology of a novel, potent, nonsteroidal estrogen receptoragonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. JMed Chem 1998; 41: 2928-31.
55. Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene inpostmenopausal women with osteoporosis. N Engl J Med 2010;362: 686-96.
56. Levenson AS, Jordan VC. MCF-7: the first hormone-responsivebreast cancer cell line. Cancer Res 1997; 57: 3071-8.
57. Black LJ, Jones CD, Falcone JF. Antagonism of estrogen actionwith a new benzothiophene derived antiestrogen. Life Sci 1983; 32:1031-6.
58. Gottardis MM, Ricchio ME, Satyaswaroop PG, Jordan VC. Effectof steroidal and nonsteroidal antiestrogens on the growth of atamoxifen-stimulated human endometrial carcinoma (EnCa101) inathymic mice. Cancer Res 1990; 50: 3189-92.
59. Jordan VC, Lababidi MK, Mirecki DM. Anti-oestrogenic and antitumourproperties of prolonged tamoxifen therapy in C3H/OUJmice. Eur J Cancer 1990; 26: 718-21.
60. Jordan VC, Lababidi MK, Langan-Fahey S. Suppression of mousemammary tumorigenesis by long-term tamoxifen therapy. J NatlCancer Inst 1991; 83: 492-6.
61. Beall PT, Misra LK, Young RL, Spjut HJ, Evans HJ, LeBlanc A. Clomiphene protects against osteoporosis in the matureovariectomized rat. Calcif Tissue Int 1984; 36: 123-5.
62. Turner RT, Wakley GK, Hannon KS, Bell NH. Tamoxifen preventsthe skeletal effects of ovarian hormone deficiency in rats. J BoneMiner Res 1987; 2: 449-56.
63. Turner RT, Wakley GK, Hannon KS, Bell NH. Tamoxifen inhibitsosteoclast-mediated resorption of trabecular bone in ovarianhormone-deficient rats. Endocrinology 1988; 122: 1146-50.
64. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifenprophylaxis for breast cancer--96-month follow-up of therandomized IBIS-I trial. J Natl Cancer Inst 2007; 99: 272-82.
65. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for theprevention of breast cancer: current status of the National SurgicalAdjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst2005; 97: 1652-62.
66. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-yearfollow-up of the Royal Marsden randomized, double-blindedtamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007;99: 283-90.
67. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDLcholesterol by 25% to 60% in patients with primaryhypercholesterolemia by atorvastatin, a new HMG-CoA reductaseinhibitor. Arterioscler Thromb Vasc Biol 1995; 15: 678-82.
68. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998; 97: 946-52.
69. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronarydisease: a meta-analysis of randomized controlled trials. JAMA1999; 282: 2340-6.
70. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs forprimary prevention of coronary heart disease: meta-analysis ofrandomised trials. BMJ 2000; 321: 983-6.
71. Steinberg D, Avigan J, Feigelson EB. Effects of Triparanol (Mer-29) on Cholesterol Biosynthesis and on Blood Sterol Levels inMan. J Clin Invest 1961; 40: 884-93.
72. Kirby TJ. Cataracts produced by triparanol. (MER-29). Trans AmOphthalmol Soc 1967; 65: 494-543.
73. Love RR, Mamby CC, Feyzi JM. Tamoxifen-induced decreases intotal cholesterol with 2 weeks of treatment. J Natl Cancer Inst1993; 85: 1344-5.
74. Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ. Effects of tamoxifen on cardiovascular risk factors inpostmenopausal women after 5 years of treatment. J Natl CancerInst 1994; 86: 1534-9.
75. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidityamong postmenopausal women with early-stage breast cancer in arandomized trial of adjuvant tamoxifen. The Stockholm BreastCancer Study Group. J Natl Cancer Inst 1993; 85: 1398-406.
76. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvanttamoxifen for breast cancer in a randomised trial. The ScottishCancer Trials Breast Group. BMJ 1995; 311: 977-80.
77. Hackshaw A, Roughton M, Forsyth S, et al. Long-term benefits of5 years of tamoxifen: 10-year follow-up of a large randomized trialin women at least 50 years of age with early breast cancer. J ClinOncol 2011; 29: 1657-63.
78. Esteva FJ, Hortobagyi GN. Comparative assessment of lipid effectsof endocrine therapy for breast cancer: implications forcardiovascular disease prevention in postmenopausal women. Breast 2006; 15: 301-12.
79. Lewis L, Jordan V, 103-21. Comprehensive Medicinal Chemistry. In: Taylor J, Triggle D, Eds. Case Histories: Raloxifene. Oxford, UK: Elsevier Limited 2006; pp. 103-21.
80. Black LJ, Sato M, Rowley ER, et al. Raloxifene (LY139481 HCI)prevents bone loss and reduces serum cholesterol without causinguterine hypertrophy in ovariectomized rats. J Clin Invest 1994; 93:63-9.
81. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifeneon cardiovascular events and breast cancer in postmenopausalwomen. N Engl J Med 2006; 355: 125-37.
82. Jensen EV, Jacobson HI. Basic guides to the mechanism ofestrogen action. Recent Progr Hormone Res 1962; 18: 387-414.
83. Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J. Sequence and expression of human estrogen receptorcomplementary DNA. Science 1986; 231: 1150-4.
84. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996; 93: 5925-30.
85. Kuiper GG, Carlsson B, Grandien K, et al. Comparison ofthe ligand binding specificity and transcript tissue distributionof estrogen receptors alpha and beta. Endocrinology 1997; 138:863-70.
86. Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P, RochefortH. Decreased expression of estrogen receptor beta protein inproliferative preinvasive mammary tumors. Cancer Res 2001; 61:2537-41.
87. Shaaban AM, O'Neill PA, Davies MP, et al. Declining estrogenreceptor-beta expression defines malignant progression of humanbreast neoplasia. Am J Surg Pathol 2003; 27: 1502-12.
88. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor beta inhibits human breast cancercell proliferation and tumor formation by causing a G2 cell cyclearrest. Cancer Res 2004; 64: 423-8.
89. Acconcia F, Totta P, Ogawa S, et al. Survival versus apoptotic17beta-estradiol effect: role of ER alpha and ER beta activated nongenomicsignaling. J Cell Physiol 2005; 203: 193-201.
90. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S. Differential response of estrogen receptor alpha andestrogen receptor beta to partial estrogen agonists/antagonists. MolPharmacol 1998; 54: 105-12.
91. McInerney EM, Weis KE, Sun J, Mosselman S, KatzenellenbogenBS. Transcription activation by the human estrogen receptorsubtype beta (ER beta) studied with ER beta and ER alpha receptorchimeras. Endocrinology 1998; 139: 4513-22.
92. Hall JM, McDonnell DP. The estrogen receptor beta-isoform(ERbeta) of the human estrogen receptor modulates ERalphatranscriptional activity and is a key regulator of the cellularresponse to estrogens and antiestrogens. Endocrinology 1999; 140:5566-78.
93. Paech K, Webb P, Kuiper GG, et al. Differential ligand activationof estrogen receptors ERalpha and ERbeta at AP1 sites [seecomments]. Science 1997; 277: 1508-10.
94. Onate SA, Tsai SY, Tsai MJ, O'Malley BW. Sequence andcharacterization of a coactivator for the steroid hormone receptorsuperfamily. Science 1995; 270: 1354-7.
95. Smith CL, O'Malley BW. Coregulator function: a key tounderstanding tissue specificity of selective receptor modulators. Endocrine Rev 2004; 25: 45-71.
96. Jordan VC. Antiestrogens and selective estrogen receptormodulators as multifunctional medicines. 2. Clinical considerationsand new agents. J Med Chem 2003; 46: 1081-111.
97. Kraichely DM, Sun J, Katzenellenbogen JA, Katzenellenbogen BS. Conformational changes and coactivator recruitment by novelligands for estrogen receptor-alpha and estrogen receptor-beta:correlations with biological character and distinct differencesamong SRC coactivator family members. Endocrinology 2000;141: 3534-45.
98. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL. The structural basis of estrogen receptor/co-activatorrecognition and the antagonism of this interaction by tamoxifen. Cell 1998; 95: 927-37.
99. Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis ofagonism and antagonism in the oestrogen receptor. Nature 1997;389: 753-8.
100. Wijayaratne AL, Nagel SC, Paige LA, et al. Comparative analysesof mechanistic differences among antiestrogens. Endocrinology1999; 140: 5828-40.
101. Lonard DM, O'Malley BW. The expanding cosmos of nuclearreceptor coactivators. Cell 2006; 125: 411-4.
102. Sun Y. E3 Ubiquitin Ligases as Cancer Targets and Biomarkers. Neoplasia 2006; 8: 645-54.
103. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactordynamics and sufficiency in estrogen receptor-regulatedtranscription. Cell 2000; 103: 843-52.
104. Jordan VC, Dix CJ, Rowsby L, Prestwich G. Studies on themechanism of action of the nonsteroidal antioestrogen tamoxifen(I.C.I. 46,474) in the rat. Mol Cell Endocrinol 1977; 7: 177-92.
105. Horwitz KB, McGuire WL. Nuclear mechanisms of estrogenaction. Effects of estradiol and anti-estrogens on estrogen receptorsand nuclear receptor processing. J Biol Chem 1978; 253: 8185-91.
106. Wijayaratne AL, McDonnell DP. The human estrogen receptoralphais a ubiquitinated protein whose stability is affecteddifferentially by agonists, antagonists, and selective estrogenreceptor modulators. J Biol Chem 2001; 276: 35684-92.
107. Wu RC, Smith CL, O'Malley BW. Transcriptional Regulation bySteroid Receptor Coactivator Phosphorylation. Endocrine Rev2006; 26: 393-9.
108. Osborne CK, Bardou V, Hopp TA, et al. Role of the estrogenreceptor coactivator AIB1 (SRC3) and HER2/neu in tamoxifenresistance in breast cancer. J Natl Cancer Inst 2003; 95: 353-61.
109. Shou J, Massarweh S, Osborne CK, et al. Mechanisms ofTamoxifen Resistance: Increased Estrogen Receptor-HER2/neuCross-Talk in ER/HER2-Positive Breast Cancer. J Natl Cancer Inst2004; 96: 926-35.
110. Davies C, Godwin J, Gray R, et al. Relevance of breast cancerhormone receptors and other factors to the efficacy of adjuvanttamoxifen: patient-level meta-analysis of randomised trials. Lancet2011; 378: 771-84.
111. Sawaki M, Wada M, Sato Y, et al. High-dose toremifene as firstlinetreatment of metastatic breast cancer resistant to adjuvantaromatase inhibitor: A multicenter phase II study. Oncol Lett 2012;3: 61-5.
112. Holli K, Valavaara R, Blanco G, et al. Safety and efficacy resultsof a randomized trial comparing adjuvant toremifene and tamoxifenin postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. J Clin Oncol 2000; 18: 3487-94.
113. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen forprevention of breast cancer: report of the National SurgicalAdjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst1998; 90: 1371-88.
114. Siris ES, Harris ST, Eastell R, et al. Skeletal effects of raloxifeneafter 8 years: results from the continuing outcomes relevant toEvista (CORE) study. J Bone Miner Res 2005; 20: 1514-24.
115. Martino S, Cauley JA, Barrett-Connor E, et al. Continuingoutcomes relevant to Evista: breast cancer incidence inpostmenopausal osteoporotic women in a randomized trial ofraloxifene. J Natl Cancer Inst 2004; 96: 1751-61.
116. Goldstein SR. Not all SERMs are created equal. Menopause 2006;13: 325-7.
117. Jordan VC. Designer estrogens. Sci Am 1998; 279: 60-7.
118. Bain RR, Jordan VC. Identification of a new metabolite oftamoxifen in patient serum during breast cancer therapy. BiochemPharmacol 1983; 32: 373-5.
119. Jordan VC, Bain RR, Brown RR, Gosden B, Santos MA. Determination and pharmacology of a new hydroxylated metaboliteof tamoxifen observed in patient sera during therapy for advancedbreast cancer. Cancer Res 1983; 43: 1446-50.
120. Hard GC, Iatropoulos MJ, Jordan K, et al. Major difference in thehepatocarcinogenicity and DNA adduct forming ability betweentoremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res1993; 53: 4534-41.
121. Lednicer D, Lyster SC, Aspergren BD, Duncan GW. Mammalianantifertility agents. 3. 1-Aryl-2-phenyl-1,2,3,4-tetrahydro-1-naphthols, 1-aryl-2-phenyl-3,4-dihydronaphthalenes, and theirderivatives. J Med Chem 1966; 9: 172-6.
122. Lednicer D, Lyster SC, Duncan GW. Mammalian antifertilityagents. IV. Basic 3,4-dihydronaphthalenes and 1,2,3,4-tetrahydro-1-naphthols. J Med Chem 1967; 10: 78-84.
123. Legha SS, Slavik M, Carter SK. Nafoxidine--an antiestrogen forthe treatment of breast cancer. Cancer 1976; 38: 1535-41.
124. Robinson SP, Koch R, Jordan VC. In vitro estrogenic actions in ratand human cells of hydroxylated derivatives of D16726(zindoxifene), an agent with known antimammary cancer activityin vivo. Cancer Res 1988; 48: 784-7.
125. Gradishar W, Glusman J, Lu Y, Vogel C, Cohen FJ, Sledge GW Jr. Effects of high dose raloxifene in selected patients with advancedbreast carcinoma. Cancer 2000; 88: 2047-53.
126. Qu Q, Harkonen PL, Vaananen HK. Comparative effects ofestrogen and antiestrogens on differentiation of osteoblasts inmouse bone marrow culture. J Cell Biochem 1999; 73: 500-7.
127. Qu Q, Zheng H, Dahllund J, et al. Selective estrogenic effects of anovel triphenylethylene compound, FC1271a, on bone, cholesterollevel, and reproductive tissues in intact and ovariectomized rats. Endocrinology 2000; 141: 809-20.
128. Hellmann-Blumberg U, Taras TL, Wurz GT, DeGregorio MW. Genotoxic effects of the novel mixed antiestrogen FC-1271a incomparison to tamoxifen and toremifene. Breast Cancer Res Treat2000; 60: 63-70.
129. DeGregorio MW, Wurz GT, Taras TL, Erkkola RU, Halonen KH, Huupponen RK. Pharmacokinetics of (deaminohydroxy)toremifenein humans: a new, selective estrogen-receptor modulator. Eur JClin Pharmacol 2000; 56: 469-75.
130. Voipio SK, Komi J, Kangas L, Halonen K, DeGregorio MW, Erkkola RU. Effects of ospemifene (FC-1271a) on uterineendometrium, vaginal maturation index, and hormonal status inhealthy postmenopausal women. Maturitas 2002; 43: 207-14.
131. Rutanen EM, Heikkinen J, Halonen K, Komi J, Lammintausta R, Ylikorkala O. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life inpostmenopausal women: a double-blind, randomized trial. Menopause 2003; 10: 433-9.
132. Ylikorkala O, Cacciatore B, Halonen K, et al. Effects ofospemifene, a novel SERM, on vascular markers and function inhealthy, postmenopausal women. Menopause 2003; 10: 440-7.
133. Komi J, Heikkinen J, Rutanen EM, Halonen K, Lammintausta R, Ylikorkala O. Effects of ospemifene, a novel SERM, onbiochemical markers of bone turnover in healthy postmenopausalwomen. Gynecol Endocrinol 2004; 18: 152-8.
134. Komi J, Lankinen KS, Harkonen P, et al. Effects of ospemifeneand raloxifene on hormonal status, lipids, genital tract, andtolerability in postmenopausal women. Menopause 2005; 12:202-9.
135. Komi J, Lankinen KS, DeGregorio M, et al. Effects of ospemifeneand raloxifene on biochemical markers of bone turnover inpostmenopausal women. J Bone Miner Metab 2006; 24: 314-8.
136. Taras TL, Wurz GT, DeGregorio MW. In vitro and in vivo biologiceffects of Ospemifene (FC-1271a) in breast cancer. J SteroidBiochem Mol Biol 2001; 77: 271-9.
137. Namba R, Young LJ, Maglione JE, et al. Selective estrogenreceptor modulators inhibit growth and progression ofpremalignant lesions in a mouse model of ductal carcinoma in situ. Breast Cancer Res 2005; 7: R881-9.
138. Wurz GT, Read KC, Marchisano-Karpman C, et al. Ospemifeneinhibits the growth of dimethylbenzanthracene-induced mammarytumors in Sencar mice. J Steroid Biochem Mol Biol 2005; 97:230-40.
139. Ke HZ, Paralkar VM, Grasser WA, et al. Effects of CP-336,156, anew, nonsteroidal estrogen agonist/antagonist, on bone, serumcholesterol, uterus and body composition in rat models. Endocrinology 1998; 139: 2068-76.
140. Maeda T, Ke HZ, Simmons H, Thompson D. Lasofoxifene, a nextgeneration estrogen receptor modulator: preclinical studies. ClinCalcium 2004; 14: 85-93.
141. Gennari L. Lasofoxifene (Pfizer). Curr Opin Investig Drugs 2005;6: 1067-78.
142. Gennari L. Lasofoxifene: a new type of selective estrogen receptormodulator for the treatment of osteoporosis. Drugs Today (Barc)2006; 42: 355-67.
143. Gennari L, Merlotti D, Martini G, Nuti R. Lasofoxifene: a thirdgenerationselective estrogen receptor modulator for the preventionand treatment of osteoporosis. Expert Opin Investig Drugs 2006;15: 1091-103.
144. Goldstein SR. Not all selective estrogen response modulators arecreated equal: update on lasofoxifene. Int J Gynecol Cancer 2006;16 Suppl 2: 504.
145. Moffett A, Ettinger M, Bolognese M, et al. Lasofoxifene, a nextgeneration SERM, is effective in preventing loss of BMD andreducing LDL-C in postmenopausal women. J Bone Min Res 2004;19: S96.
146. Davidson M, Moffett A, Welty F, et al Extraskeletal effects oflasofoxifene on postmenopausal women. J Bone Min Res 2005; 20:S173.
147. McClung M, Siris E, Cummings S. Lasofoxifene increased BMDof the spine and hip and decreased bone turnover markers inpostmenopausal women with low or normal BMD. J Bone Min Res2005; 20: F429.
148. McClung MR, Siris E, Cummings S, et al. Prevention of bone lossin postmenopausal women treated with lasofoxifene compared withraloxifene. Menopause 2006; 13: 377-86.
149. Cummings S, Eastell R, Ensrud K. The effects of lasofoxifene onfractures and breast cancer: 3 year results from the PEARL trial. JBone Miner Res 2008; 23: S81.
150. LaCroix AZ, Powles T, Osborne CK, et al. Breast cancer incidencein the randomized PEARL trial of lasofoxifene in postmenopausalosteoporotic women. J Natl Cancer Inst 2010; 102: 1706-15.
151. Gennari L. Lasofoxifene, a new selective estrogen receptormodulator for the treatment of osteoporosis and vaginal atrophy. Expert Opin Pharmacother 2009; 10: 2209-20.
152. Miller CP, Collini MD, Tran BD, et al. Design, synthesis, andpreclinical characterization of novel, highly selective indoleestrogens. J Med Chem 2001; 44: 1654-7.
153. Gruber C, Gruber D. Bazedoxifene (Wyeth). Curr Opin InvestigDrugs 2004; 5: 1086-93.
154. Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, LyttleCR. Bazedoxifene acetate: a selective estrogen receptor modulatorwith improved selectivity. Endocrinology 2005; 146: 3999-4008.
155. Smith S, Minck D, Jolette J, et al. Bazedoxifene preventsovariectomy-induced bone loss in the Cynomolgus monkey. J BoneMiner Res 2005; 20: S174.
156. Komm B, Kharode Y, Bodine P, et al. Bazedoxifene + conjugatedestrogens: a balanced combination to provide optimal estrogenic"safety" and efficacy. J Bone Miner Res 2003; 18: S272.
157. Komm B, Kharode Y, Bodine P, et al. Combining a SERM withconjugated estrogens (CE) to improve the SERM profile: not allSERMs may succeed. J Bone Miner Res 2003; 25: S273.
158. Kharode Y, Green P, Marzolf J, et al. Comparison of the effects ofbazedoxifene, raloxifene, lasofoxifene and risedronate, cotreatmenton h-PTH-induced reversal of established osteopenia inovariectomized rats. J Bone Miner Res 2003; 18: S273.
159. Miller PD, Chines AA, Christiansen C, et al. Effects ofbazedoxifene on BMD and bone turnover in postmenopausalwomen: 2-yr results of a randomized, double-blind, placebo-, andactive-controlled study. J Bone Miner Res 2008; 23: 525-35.
160. Silverman SL, Christiansen C, Genant HK, et al. Efficacy ofbazedoxifene in reducing new vertebral fracture risk inpostmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J BoneMiner Res 2008; 23: 1923-34.
161. Pinkerton JV, Archer DF, Utian WH, et al. Bazedoxifene effects onthe reproductive tract in postmenopausal women at risk forosteoporosis. Menopause 2009; 16: 1102-8.
162. Archer DF, Pinkerton JV, Utian WH, et al. Bazedoxifene, aselective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporoticpostmenopausal women. Menopause 2009; 16: 1109-15.
163. de Villiers TJ, Chines AA, Palacios S, et al. Safety and tolerabilityof bazedoxifene in postmenopausal women with osteoporosis:results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 2011; 22: 567-76.
164. Grady D, Ettinger B, Moscarelli E, et al. Safety and adverse effectsassociated with raloxifene: multiple outcomes of raloxifeneevaluation. Obstet Gynecol 2004; 104: 837-44.
165. Dodge JA, Lugar CW, Cho S, et al. Evaluation of the majormetabolites of raloxifene as modulators of tissue selectivity. JSteroid Biochem Mol Biol 1997; 61: 97-106.
166. Grese TA, Cho S, Finley DR, et al. Structure-activity relationshipsof selective estrogen receptor modulators: modifications to the2-arylbenzothiophene core of raloxifene. J Med Chem 1997; 40:146-67.
167. Grese TA, Sluka JP, Bryant HU, et al. Molecular determinants oftissue selectivity in estrogen receptor modulators. Proc Natl AcadSci USA 1997; 94: 14105-10.
168. Palkowitz AD, Glasebrook AL, Thrasher KJ, et al. Discovery andsynthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator. J Med Chem 1997; 40:1407-16.
169. Grese TA, Pennington LD, Sluka JP, et al. Synthesis andpharmacology of conformationally restricted raloxifene analogues:highly potent selective estrogen receptor modulators. J Med Chem1998; 41: 1272-83.
170. Sato M, Turner CH, Wang T, Adrian MD, Rowley E, Bryant HU. LY353381. HCl: a novel raloxifene analog with improved SERMpotency and efficacy in vivo. J Pharmacol Exp Ther 1998; 287: 1-7.
171. Bryant HU, Glasebrook AL, Yang NN, Sato M. An estrogenreceptor basis for raloxifene action in bone. J Steroid Biochem MolBiol 1999; 69: 37-44.
172. Munster PN. Arzoxifene: the development and clinical outcome ofan ideal SERM. Expert Opin Investig Drugs 2006; 15: 317-26.
173. Dardes RC, Bentrem D, O'Regan RM, Schafer JM, Jordan VC. Effects of the new selective estrogen receptor modulatorLY353381. HCl (Arzoxifene) on human endometrial cancer growthin athymic mice. Clin Cancer Res 2001; 7: 4149-55.
174. Suh N, Glasebrook AL, Palkowitz AD, et al. Arzoxifene, a newselective estrogen receptor modulator for chemoprevention ofexperimental breast cancer. Cancer Res 2001; 61: 8412-5.
175. Detre S, Riddler S, Salter J, A'Hern R, Dowsett M, Johnston SR. Comparison of the selective estrogen receptor modulatorarzoxifene (LY353381) with tamoxifen on tumor growth andbiomarker expression in an MCF-7 human breast cancer xenograftmodel. Cancer Res 2003; 63: 6516-22.
176. Licun W, Tannock IF. Selective estrogen receptor modulators asinhibitors of repopulation of human breast cancer cell lines afterchemotherapy. Clin Cancer Res 2003; 9: 4614-8.
177. Freddie CT, Larsen SS, Bartholomaeussen M, Lykkesfeldt AE. Theeffect of the new SERM arzoxifene on growth and gene expressionin MCF-7 breast cancer cells. Mol Cell Endocrinol 2004; 219: 27-36.
178. Morello KC, Wurz GT, DeGregorio MW. SERMs: current statusand future trends. Crit Rev Oncol Hematol 2002; 43: 63-76.
179. Munster PN, Buzdar A, Dhingra K, et al. Phase I study of a thirdgenerationselective estrogen receptor modulator, LY353381. HCL, in metastatic breast cancer. J Clin Oncol 2001; 19: 2002-9.
180. McMeekin DS, Gordon A, Fowler J, et al. A phase II trial ofarzoxifene, a selective estrogen response modulator, in patientswith recurrent or advanced endometrial cancer. Gynecol Oncol2003; 90: 64-9.
181. Ma YL, Bryant HU, Zeng Q, et al. Long-term dosing of arzoxifenelowers cholesterol, reduces bone turnover, and preservesbone quality in ovariectomized rats. J Bone Miner Res 2002; 17:2256-64.
182. Sato M, Zeng GQ, Rowley E, Turner CH. LY353381 x HCl:an improved benzothiophene analog with bone efficacycomplementary to parathyroid hormone-(1-34). Endocrinology1998; 139: 4642-51.
183. Downs RW Jr, Moffett AM, Ghosh A, Cox DA, Dowsett SA, Harper K. Effects of arzoxifene on bone, lipid markers, and safetyparameters in postmenopausal women with low bone mass. Osteoporos Int 2010; 21: 1215-26.
184. Kendler DL, Palacios S, Cox DA, et al. Arzoxifene versusraloxifene: effect on bone and safety parameters in postmenopausalwomen with osteoporosis. Osteoporos Int 2012; 23(3): 1091-109.
185. Bolognese M, Krege JH, Utian WH, et al. Effects of arzoxifene onbone mineral density and endometrium in postmenopausal womenwith normal or low bone mass. J Clin Endocrinol Metab 2009; 94:2284-9.
186. Black DM, Cummings SR, Karpf DB, et al. Randomised trial ofeffect of alendronate on risk of fracture in women with existingvertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-41.
187. Harris ST, Watts NB, Genant HK, et al. Effects of risedronatetreatment on vertebral and nonvertebral fractures in women withpostmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) StudyGroup. JAMA 1999; 282: 1344-52.
188. Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebocontrolled, randomized trial of the effects of alendronate on bonedensity and fracture risk in postmenopausal women with low bonemass: results of the FOSIT study. Fosamax International TrialStudy Group. Osteoporos Int 1999; 9: 461-8.
189. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronicacid for treatment of postmenopausal osteoporosis. N Engl J Med2007; 356: 1809-22.
190. Cummings SR, McClung M, Reginster JY, et al. Arzoxifene forprevention of fractures and invasive breast cancer inpostmenopausal women. J Bone Miner Res 2011; 26: 397-404.
191. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefitsof estrogen plus progestin in healthy postmenopausal women:principal results From the Women's Health Initiative randomizedcontrolled trial. JAMA 2002; 288: 321-33.
192. Cummings SR, Ettinger B, Delmas PD, et al. The effects oftibolone in older postmenopausal women. N Engl J Med 2008; 359:697-708.
193. Cirillo DJ, Wallace RB, Rodabough RJ, et al. Effect of estrogentherapy on gallbladder disease. JAMA 2005; 293: 330-9.
194. Ivanova MM, Mazhawidza W, Dougherty SM, Minna JD, KlingeCM. Activity and intracellular location of estrogen receptors alphaand beta in human bronchial epithelial cells. Mol Cell Endocrinol2009; 305: 12-21.
195. Vegeto E, Cuzzocrea S, Crisafulli C, et al. Estrogen receptor-alphaas a drug target candidate for preventing lung inflammation. Endocrinology 2010; 151: 174-84.
196. Archer DF, Lewis V, Carr BR, Olivier S, Pickar JH. Bazedoxifene/conjugated estrogens (BZA/CE): incidence ofuterine bleeding in postmenopausal women. Fertil Steril 2009; 92:1039-44.
197. Pinkerton JV, Stovall DW. Bazedoxifene when paired withconjugated estrogens is a new paradigm for treatment ofpostmenopausal women. Expert Opin Investig Drugs 2010; 19:1613-21.
198. Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-riskpostmenopausal women. Fertil Steril 2009; 92: 1045-52.
199. Crandall CJ, Aragaki AK, Cauley JA, et al. Breast tenderness andbreast cancer risk in the estrogen plus progestin and estrogen-alonewomen's health initiative clinical trials. Breast Cancer Res Treat2012; 132: 275-85.
200. Narod SA. Hormone replacement therapy and the risk of breastcancer. Nat Rev Clin Oncol 2011; 8: 669-76.
201. Jordan VC, Brodie AM. Development and evolution of therapiestargeted to the estrogen receptor for the treatment and prevention ofbreast cancer. Steroids 2007; 72: 7-25.
202. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast canceroutcomes in adjuvant trials of aromatase inhibitors versustamoxifen. J Clin Oncol 2010; 28: 509-18.
203. Vogel VG. Raloxifene: a selective estrogen receptor modulator forreducing the risk of invasive breast cancer in postmenopausalwomen. Womens Health (Lond Engl) 2007; 3: 139-53.
204. Vogel VG, Costantino JP, Wickerham DL, et al. Update of theNational Surgical Adjuvant Breast and Bowel Project Study ofTamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breastcancer. Cancer Prev Res (Phila) 2010; 3: 696-706.
205. Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, ChlebowskiRT, Wactawski-Wende J, et al. Exemestane for breast-cancerprevention in postmenopausal women. N Engl J Med 2011; 364:2381-91.
206. Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ. Carpal tunnel syndrome and musculoskeletal symptoms inpostmenopausal women with early breast cancer treated withexemestane or tamoxifen after 2-3 years of tamoxifen: aretrospective analysis of the Intergroup Exemestane Study. LancetOncol 2012.
207. Watanabe N, Ikeno A, Minato H, Nakagawa H, Kohayakawa C, Tsuji J. Discovery and preclinical characterization of (+)-3-[4-(1-piperidinoethoxy)phenyl]spiro[indene-1,1'-indane]-5,5'-diolhydrochloride: a promising nonsteroidal estrogen receptor agonistfor hot flush. J Med Chem 2003; 46: 3961-4.
208. Wallace OB, Lauwers KS, Dodge JA, et al. A selective estrogenreceptor modulator for the treatment of hot flushes. J Med Chem2006; 49: 843-6.
209. Jain N, Xu J, Kanojia RM, et al. Identification and structureactivityrelationships of chromene-derived selective estrogenreceptor modulators for treatment of postmenopausal symptoms. JMed Chem 2009; 52: 7544-69.
210. Jain N, Kanojia RM, Xu J, et al. Novel chromene-derived selectiveestrogen receptor modulators useful for alleviating hot flushes andvaginal dryness. J Med Chem 2006; 49: 3056-9.
211. Meegan MJ, Lloyd DG. Advances in the science of estrogenreceptor modulation. Curr Med Chem 2003; 10: 181-210.
212. Arevalo MA, Santos-Galindo M, Lagunas N, Azcoitia I, Garcia-Segura LM. Selective estrogen receptor modulators as braintherapeutic agents. J Mol Endocrinol 2011; 46: R1-9.
213. Nilsson S, Gustafsson JA. Estrogen receptors: therapies targeted toreceptor subtypes. Clin Pharmacol Ther 2011; 89: 44-55.
214. Rosano C, Stec-Martyna E, Lappano R, Maggiolini M. Structurebasedapproach for the discovery of novel selective estrogenreceptor modulators. Curr Med Chem 2011; 18: 1188-94.
215. O'Malley BW. Molecular biology. Little molecules with big goals. Science 2006; 313: 1749-50.
216. Liby K, Rendi M, Suh N, et al. The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, eitherarzoxifene or acolbifene, synergizes in the prevention andtreatment of mammary tumors in an estrogen receptor-negativemodel of breast cancer. Clin Cancer Res 2006; 12: 5902-9.
217. Deshmane V, Krishnamurthy S, Melemed AS, Peterson P, BuzdarAU. Phase III double-blind trial of arzoxifene compared withtamoxifen for locally advanced or metastatic breast cancer. J ClinOncol 2007; 25: 4967-73.
218. Fabian CJ, Kimler BF, Anderson J, et al. Breast cancerchemoprevention phase I evaluation of biomarker modulation byarzoxifene, a third generation selective estrogen receptormodulator. Clin Cancer Res 2004; 10: 5403-17.
219. Cohen LA, Pittman B, Wang CX, Aliaga C, Yu L, Moyer JD. LAS, a novel selective estrogen receptor modulator withchemopreventive and therapeutic activity in the N-nitroso-Nmethylurea-induced rat mammary tumor model. Cancer Res 2001;61: 8683-8.
220. Ronkin S, Northington R, Baracat E, et al. Endometrial effects ofbazedoxifene acetate, a novel selective estrogen receptormodulator, in postmenopausal women. Obstet Gynecol 2005; 105:1397-404.